吴伟

    【摘要】 小细胞肺癌(small cell lung cancer，SCLC)是肺癌中恶性程度较高的一种亚型，其临床预后较差。免疫检查点抑制剂(immune checkpoint inhibitors，ICIs)阿特珠单抗(Atezolizumab)联合化疗能够显著提高SCLC患者的总体生存率(overall survival，OS)，已被批准用于广泛期SCLC的一线治疗。与非小细胞肺癌相较而言，免疫治疗目前在小细胞肺癌中的应用价值仍较局限。因此，本文就SCLC的免疫微环境，ICIs在SCLC中的临床试验和疗效预测标志物以及最新的免疫联合治疗试验做简要综述，以期为临床SCLC免疫治疗的诊疗方案提供新的思路。

    【关键词】 小细胞肺癌 免疫检查点抑制剂 预测标志物 免疫治疗

    Application Progress of Immune Checkpoint Inhibitors in Small Cell Lung Cancer/WU Wei. //Medical Innovation of China， 2022， 19(04)： -188

    [Abstract] Small cell lung cancer (SCLC) is a subtype of lung cancer with high malignancy and poor prognosis. Immune checkpoint inhibitors (ICIs) Atezolizumab combined with chemotherapy can significantly improve the overall survival of SCLC patients， and has been approved for the first-line treatment of extensive-stage SCLC patients. The clinical value of immunotherapy is still limited in SCLC comparing with non-small cell lung cancer. Therefore， this paper briefly reviewed the immune microenvironment of SCLC ......